Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.
about
Live attenuated vaccines for invasive Salmonella infectionsInsights into substrate binding and catalysis in bacterial type I dehydroquinaseComplex adaptive immunity to enteric fevers in humans: lessons learned and the path forwardIrreversible covalent modification of type I dehydroquinase with a stable Schiff baseA new generation of stable, nonantibiotic, low-copy-number plasmids improves immune responses to foreign antigens in Salmonella enterica serovar Typhi live vectorsComparison of the abilities of different attenuated Salmonella typhimurium strains to elicit humoral immune responses against a heterologous antigen.Genetic control of immune response to recombinant antigens carried by an attenuated Salmonella typhimurium vaccine strain: Nramp1 influences T-helper subset responses and protection against leishmanial challenge.Oral vaccination against tetanus: comparison of the immunogenicities of Salmonella strains expressing fragment C from the nirB and htrA promoters.The Salmonella typhimurium AhpC polypeptide is not essential for virulence in BALB/c mice but is recognized as an antigen during infectionIdentification of three highly attenuated Salmonella typhimurium mutants that are more immunogenic and protective in mice than a prototypical aroA mutantThe nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice.In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors.Salmonella enterica serovar typhimurium surA mutants are attenuated and effective live oral vaccinesPhase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers.Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915.Cell-associated flagella enhance the protection conferred by mucosally-administered attenuated Salmonella Paratyphi A vaccines.Humanized nonobese diabetic-scid IL2rgammanull mice are susceptible to lethal Salmonella Typhi infection.Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers.Salmonella enterica serovar Typhi live vector vaccines delivered intranasally elicit regional and systemic specific CD8+ major histocompatibility class I-restricted cytotoxic T lymphocytes.Selection of Salmonella enterica serovar Typhi genes involved during interaction with human macrophages by screening of a transposon mutant libraryVaccination of chickens with strain CVL30, a genetically defined Salmonella enteritidis aroA live oral vaccine candidateConstruction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccineExpression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strainSalmonella typhi stimulation of human intestinal epithelial cells induces secretion of epithelial cell-derived interleukin-6.Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system.Toxicity of lipopolysaccharide and of soluble extracts of Salmonella typhimurium in mice immunized with a live attenuated aroA salmonella vaccine.Vaccination Method Affects Immune Response and Bacterial Growth but Not Protection in the Salmonella Typhimurium Animal Model of Typhoid.Designing Irreversible Inhibitors--Worth the Effort?Construction, expression, and immunogenicity of the Schistosoma mansoni P28 glutathione S-transferase as a genetic fusion to tetanus toxin fragment C in a live Aro attenuated vaccine strain of Salmonella.Vaccination against typhoid fever: present statusAttenuating gene expression (AGE) for vaccine developmentSalmonella enterica serovar Typhi live vector vaccines finally come of ageRecombinant Salmonella enterica serovar Typhimurium as a vaccine vector for HIV-1 Gag.Live Attenuated Human Salmonella Vaccine Candidates: Tracking the Pathogen in Natural Infection and Stimulation of Host ImmunityHow to become a top model: impact of animal experimentation on human Salmonella disease research.Specific chemical modification of bacterial type I dehydroquinase--opportunities for drug discovery.Animal Models for Salmonellosis: Applications in Vaccine ResearchGeneration of specific effector and memory T cells with gut- and secondary lymphoid tissue- homing potential by oral attenuated CVD 909 typhoid vaccine in humans.
P2860
Q27003066-F1CFF73A-9F02-41DF-B70A-ACCB4F4BF1EEQ27690793-D33E330D-2234-49A7-B20E-1A4544C72CA0Q27694492-407FB24B-AEEC-413A-8EFD-82BEE9874B67Q27696136-AF0F972E-B29C-4D5F-BD0A-F31DF3988425Q33557714-7E4C7873-01E1-4DF7-9F65-240BCDEC589EQ33750518-0790EB8B-D3C5-4F59-8915-F7D655E65E13Q33753467-C106CCE9-44C5-4476-8110-98C7E4BAAD10Q33755979-6520B4B7-4650-4059-BFE4-E45821FF4C22Q33756294-7C10B434-C9F9-49EB-BCDD-60B5D0138EB6Q33756680-EECCFE38-DF65-4644-A1FA-A0C58524EFDEQ33877406-2DFBC2DB-A486-428E-903F-712F8DC454DAQ34003031-6CC8F0F6-F797-4249-BD9F-89D5AF20A37DQ34003465-048223F7-86B7-4850-A7B3-D08599C99FA3Q34003500-122A9737-5F2E-45A5-8B8A-ECA49F04493FQ34007802-B40C32F5-BE85-46FE-A8C4-25BFD7E57501Q34008449-5F7B3974-239A-491B-BEC2-3525FFC6400DQ34070619-D8B1ECDA-B2D0-4461-B3B4-A4BF1B2A32EEQ34100373-A5A449B9-83C6-4B25-957E-A50F89151783Q34125990-58C8E52A-C125-41F1-AA25-5F0E84D012ECQ34127550-7663F76B-F0B1-4A96-9DBC-9DFA43C37648Q34264861-9B135298-005A-4E40-86F3-00C5F6751983Q34543536-F6186987-51F0-4263-A790-899A048074AAQ34545910-9D9AF8F9-F036-4C68-B7E1-D0298153D14DQ35524357-E43DB70C-8A09-47C8-99E0-0535CD091124Q35532132-D719EF26-A480-4789-AEA2-8434D2E40B08Q35534558-71CE9698-2CC7-4297-ABB3-7948FD8E7EC7Q35553394-55862BFF-E7BF-4BB2-929F-30E9E2AE5A5CQ35781875-5829B002-85C9-4BA9-BB5E-25AB723B0B9AQ35824212-3E0097C5-EB96-45A4-BD36-3F05A8197665Q35848315-9A6EB0DD-E992-4CFC-B0C0-3F16FBBF3C7BQ35904338-1A557AFE-B43C-4FC4-9870-9AA82B26FC36Q36794750-5092F028-8A18-4008-95BE-AA9C03F90D56Q37021492-C60FEB71-8106-41D5-9871-482D14D82B65Q37106127-83DA1419-9221-43F1-94F1-0C1FD7AC87F7Q37235277-DEF2FEFA-2A77-4CBB-A308-5B994ADA7A42Q37429384-76D56994-844D-4495-81FB-321A7E0CE415Q37845999-59A23268-87B1-403B-906A-AEA0C63024ECQ38645421-EB8229A0-C50D-4DF6-89CC-4DDCEF57BD8DQ38896014-4FDBA3AF-303B-4D3E-B8B5-D6A0210979D6Q39081934-B3BD2440-660E-4D5B-9FEE-BF9F6271AC15
P2860
Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.
@en
Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.
@nl
type
label
Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.
@en
Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.
@nl
prefLabel
Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.
@en
Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.
@nl
P2093
P1433
P1476
Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.
@en
P2093
P304
P356
10.1016/0264-410X(92)90392-W
P407
P577
1992-01-01T00:00:00Z